ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08905
-0,05%
Bitcoin
66.920,60
-0,24%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Virax Biolabs Group Ltd (VRAX)

  7. Virax Biolabs Group Ltd (VRAX) News

VRAX

Virax Biolabs (VRAX)

Virax Biolabs Group Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:VRAX
DatumZeitQuelleÜberschriftSymbolFirma
25/04/202414h00PR Newswire (US)Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024NASDAQ:VRAXVirax Biolabs Group Ltd
16/04/202413h30PR Newswire (US)Virax Biolabs to Participate at ESCMID Global 2024NASDAQ:VRAXVirax Biolabs Group Ltd
15/03/202421h30PR Newswire (US)Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price DeficiencyNASDAQ:VRAXVirax Biolabs Group Ltd
22/01/202423h28Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
22/01/202423h27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VRAXVirax Biolabs Group Ltd
12/01/202413h43Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
21/12/202313h34Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
21/12/202313h30PR Newswire (US)Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID PatientsNASDAQ:VRAXVirax Biolabs Group Ltd
20/12/202322h12Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VRAXVirax Biolabs Group Ltd
20/12/202322h12Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VRAXVirax Biolabs Group Ltd
20/12/202322h06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
20/12/202322h03Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VRAXVirax Biolabs Group Ltd
18/12/202313h37Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
18/12/202313h30PR Newswire (US)Virax Biolabs' CEO James Foster Issues Letter to ShareholdersNASDAQ:VRAXVirax Biolabs Group Ltd
18/12/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VRAXVirax Biolabs Group Ltd
14/12/202313h43Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
14/12/202313h30PR Newswire (US)Virax Biolabs Group Limited Announces 1-for-10 Share ConsolidationNASDAQ:VRAXVirax Biolabs Group Ltd
08/12/202312h03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
05/12/202322h06Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:VRAXVirax Biolabs Group Ltd
08/11/202322h11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
31/10/202321h38Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
17/10/202322h05Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:VRAXVirax Biolabs Group Ltd
12/10/202314h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
04/10/202313h24Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
12/09/202313h49Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
12/09/202313h30PR Newswire (US)Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts WebinarNASDAQ:VRAXVirax Biolabs Group Ltd
01/09/202313h37Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
01/09/202313h30PR Newswire (US)Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth MomentumNASDAQ:VRAXVirax Biolabs Group Ltd
03/08/202314h39Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
03/08/202313h30PR Newswire (US)Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 BidNASDAQ:VRAXVirax Biolabs Group Ltd
 Showing the most relevant articles for your search:NASDAQ:VRAX

Kürzlich von Ihnen besucht

EU
IWSR2
AMUNDI WSR2 INAV
USOTC
EGRGF
Eagle Energy (CE)
AMEX
IMAR
Innovator International ...
NASDAQ
CAAS
China Automotive Systems
BIT
S28990
Societe Generale Effekten
LSE
63KR
Anz Bank 5%
LSE
76SU
Natixis 31
ASX
BPS
LSE
UE43
Sg Issuer 25
DBI
ZK2H
LevDAX x9 Total Return EUR
KOSPI
000850
Hwacheon Machine Tool
TSXV
DRL.H
ASX
WECN
White Energy
LSE
IOL
ASX
PSLNB
Paterson Resources
NASDAQ
VLDR
Velodyne Lidar
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten